| Cover | Jun. 09, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | This Current Report on Form 8-K/A (this "Amendment") amends the Current Report on Form 8-K of NeuroBo Pharmaceuticals, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission on June 10, 2022 (the "Original Form 8-K"). The Original Form 8-K reported the final voting results of the Company's 2022 annual meeting of stockholders held on June 9, 2022 (the "Annual Meeting"). The sole purpose of this Amendment is to disclose the Company's decision regarding whether advisory votes on the compensation of the Company's named executive officers required by Section 14A(a)(1) of the Securities Exchange Act of 1934 and Rule 14a-21(a) promulgated thereunder (the "Say-on-Pay Vote") should be held every one, two or three years (the "Say-on-Frequency Proposal"). No other changes have been made to the Original Form 8-K. |
| Document Period End Date | Jun. 09, 2022 |
| Entity File Number | 001-37809 |
| Entity Registrant Name | NeuroBo Pharmaceuticals, Inc. |
| Entity Central Index Key | 0001638287 |
| Entity Tax Identification Number | 47-2389984 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 200 Berkeley Street |
| Entity Address, Address Line Two | 19th Floor |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02116 |
| City Area Code | 857 |
| Local Phone Number | 702-9600 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.001 per share |
| Trading Symbol | NRBO |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
